Release of cell free DNA (cfDNA) from damaged or dead cells routinely occurs in normal
physiology. Recently, cfDNA has emerged as an essential biomarker in cardiovascular …

Molecular analysis of cell-free DNA (cfDNA) that circulates in plasma and other body fluids
represents a “liquid biopsy” approach for non-invasive cancer screening or monitoring. The …

Multiplex, digital nucleic acid detections have important biomedical applications, but the
multiplexity of existing methods is predominantly achieved using fluorescent dyes or probes …

Introduction Chimeric antigen receptor T-cell (CAR-T) therapies are increasingly used to
treat relapsed B-cell lymphomas and acute lymphoblastic leukemia. Considering the …

Circulating cell-free tumor DNA (ctDNA) in the blood is DNA released from apoptotic,
circulating, and living tumor cells. ctDNA is about 140 nt in length and has a half-life of about …

Copy number aberrations (CNA) are one of the most important classes of genomic mutations
related to oncogenetic effects. In the past three decades, a vast amount of CNA data has …

Circulating tumor DNA (ctDNA) represents a small fraction of the total circulating free DNA
and its analysis is increasingly used for diagnostic, prognostic and treatment purposes of …

Objective: We assessed the status of the BRAF V600E mutation in cell-free circulating tumor
DNA (cfDNA) isolated from the plasma of patients with metastatic melanoma treated with the …

As a high-performance solution for longitudinal monitoring of patients being treated for
metastatic cancer, a single-color digital PCR (dPCR) assay that detects and quantifies …

Accurate detection of somatic variants, against a background of wild-type molecules, is
essential for clinical decision making in oncology. Existing approaches, such as allele …